---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-006222"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:05:20.606975+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech Q2 net loss narrows to $2.33M; FDA agrees on Phase 3 endpoint for ARDS drug

## Summary
- Net loss of $2.33M ($0.12/share) vs $4.57M ($0.33/share) in Q2 2022; operating expenses down 47%.
- Cash and equivalents $7.47M; working capital $6.56M; raised $0.60M via ATM after quarter end.
- FDA agreed on primary endpoint for pivotal Phase 3 study of EB05 (paridiprubart) in ARDS patients.
- Canadian regulators authorized Phase 2 study of EB06 for vitiligo; Phase 2b topline results for EB01 in ACD reported.
- Plans to file IND for Phase 2 study of EB07 in systemic sclerosis (scleroderma).

## SEC filing metadata
- accession: 0001654954-23-006222
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/0001654954-23-006222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-006222
- JSON: https://secwatch.observer/filing/0001654954-23-006222.json
- Plain text: https://secwatch.observer/filing/0001654954-23-006222.txt

## Key facts
- Earnings Releases
  Edesa Biotech, Inc. reported six months ended March 31, 2023 results: net income net loss of $4.67 million, EPS $0.24 per common share.
  - Period: six months ended March 31, 2023
  - Net income: net loss of $4.67 million
  - EPS: $0.24 per common share
  - Result: reported results
  source text: For the six months ended March 31, 2023, Edesa reported a net loss of $4.67 million, or $0.24 per common share, compared to a net loss of $8.95 million, or $0.66 per common share, for the six months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/0001654954-23-006222-index.htm
- Earnings Releases
  Edesa Biotech, Inc. reported quarter ended March 31, 2023 results: net income net loss of $2.33 million, EPS $0.12 per common share.
  - Period: quarter ended March 31, 2023
  - Net income: net loss of $2.33 million
  - EPS: $0.12 per common share
  - Result: reported results
  source text: For the quarter ended March 31, 2023, Edesa reported a net loss of $2.33 million, or $0.12 per common share, compared to a net loss of $4.57 million, or $0.33 per common share, for the quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/0001654954-23-006222-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.